Abstract: Drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent are disclosured. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: A transient electromagnetic device with variable shape and turns includes squares, a transmitting coil carrying frame, a transmitting coil, a turns-variable device, a current generator and a working power supply. The transmitting coil carrying frame is arranged inside the transmitting coil; the transmitting coil carrying frame is configured as a carrier of the transmitting coil, and configured for adjusting a side length of the transmitting coil and a shape of the transmitting coil; the square is configured for clamping and connecting the transmitting coil and the transmitting coil carrying frame to fix the transmitting coil to the transmitting coil carrying frame. The current generator is configured for generating transient current; the turns-variable device is configured for changing the turns of the transmitting coil; and the transmitting coil is configured for transmitting the transient current to a target area to be measured.

Abstract: A native leaflet treatment system and method for treating native heart valve leaflets before heart valve repair or replacement procedure. The treatment system includes a delivery apparatus configured to enter the heart, and a native leaflet treatment device stored in the delivery apparatus in a compressed state. The treatment device includes a clamping structure, which is configured to retain at least a portion of the native leaflets in the deployed state. The treatment device is delivered into the heart using the delivery apparatus, and released near the native heart valve, where the treatment device expands and the clamping structure captures and holds the native leaflet, such that the native leaflets will no longer block blood flow. This improves the dynamics of the blood flow which facilitates subsequent surgical procedures (minimally-invasive surgery or open surgery) for heart valve repair or replacement.

Abstract: The present application relates to a balloon catheter, which is a rapid exchange structure and has a balloon catheter body and a hub, wherein the balloon catheter body has a push member, a transition member, a balloon loading member, a balloon, a imaging mark and a tip head, the balloon loading member comprises an outer tube and an inner tube, a distal end of the handle is connected with a proximal end of the push member, a proximal end of the transition member extends from a distal end of the push member, a distal end of the transition member is nested inside a proximal end of the outer tube of the balloon loading member, the balloon loading member loads the balloon, the tip head is provided on a distal end of the balloon, the imaging mark is provided on the balloon loading member, characterized in that the balloon has a wall thickness of 10-15 microns, the balloon has a nominal dilation pressure of 3-4 atm, and the balloon catheter has a rated burst pressure of is 10-12 atm.

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: Disclosed in this specification are a protein-based foaming agent, its preparation method and application, and belong to the technical field of food additives. The foaming agent comprises raw materials of alpha-lactalbumin (?-La) and glycyrrhizic acid (GA), where a molar concentration ratio of ?-La to GA in the protein-based foaming agent is 1 : (2.5-750); the foaming agent is prepared as follows: preparing ?-La solution, adjusting pH, and then adding GA for reaction to obtain the protein-based foaming agent. In some embodiments of this specification, the ?-La undergoes changes in terms secondary and tertiary structures by adjusting the pH of ?-La solution, which promotes the development of protein molecules and increases the possibility of binding ?-La with micromolecule surfactants; after ?-La is bound with GA, the foaming ability and foam stability are greatly improved.

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipateldisappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: The present invention provides a transapical implantable mitral valve device, which includes an outer valve stent comprising an outer valve stent body that is composed of a plurality of first structure units arranged in the circumferential direction and an anchoring unit that is disposed on the outer valve stent body for anchoring the mitral valve device in a human body, at least one of an inner surface and an outer surface of the outer valve stent body being covered with an outer skirt; an inner valve stent disposed inside the outer valve stent and interconnected with the outer valve stent, a cavity being formed between the outer valve stent and the inner valve stent; and a valve leaflet structure disposed in the inner valve stent to form a prosthetic valve.

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: The present application relates to a balloon catheter, which is a rapid exchange structure and has a balloon catheter body and a hub, wherein the balloon catheter body has a push member, a transition member, a balloon loading member, a balloon, a imaging mark and a tip head, the balloon loading member comprises an outer tube and an inner tube, a distal end of the handle is connected with a proximal end of the push member, a proximal end of the transition member extends from a distal end of the push member, a distal end of the transition member is nested inside a proximal end of the outer tube of the balloon loading member, the balloon loading member loads the balloon, the tip head is provided on a distal end of the balloon, the imaging mark is provided on the balloon loading member, characterized in that the balloon has a wall thickness of 10-15 microns, the balloon has a nominal dilation pressure of 3-4 atm, and the balloon catheter has a rated burst pressure of is 10-12 atm.

Abstract: The invention relates to an apparatus for breaking thrombus and aspirating the thrombus comprising: an aspirating rotary grinding hand-held system which integrates a rotary grinding head driving device, an aspirating device, a power supply device and a control device; a micro catheter device which is communicated with the aspirating device and the rotary grinding head driving device, respectively; a waste liquid collecting device which is connected to the aspirating device, wherein the aspirating device and the waste liquid collecting device form an airtight passage; and a distal end rotary grinding head device which is connected to the rotary grinding head driving device through a connection mandrel, wherein the power supply device provides power for the rotary grinding head driving device; wherein the distal end rotary grinding head device and the connection mandrel are accommodated in an inner cavity of the micro catheter device; and wherein the control device controls the aspirating device and the rotary

Abstract: Medical devices and methods for endovascularly or transcatheterly replacing a patient's heart valve, including: a delivery system (9) having an entry profile of 30 Fr or less; a self-expandable annulus ring (10) disposed in the delivery system (9) including a self-expandable anchoring and clipping structure and multiple bridges (4) connected to the anchoring and clipping structure; and a replacement heart valve (11) disposed in the delivery system (9) and connected to the bridges (4). The bridges (4) are formed of a shape memory material; during deployment, the bridges (4) fold upwardly inside the self-expandable anchoring and clipping structure to lift the replacement heart valve (11) into position.

Abstract: Drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent are disclosured. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: A mitral valve replacement device is adapted to be deployed at a mitral valve position in a human heart. The device has an atrial flange defining an atrial end of the device, a ventricular portion defining a ventricular end of the device, the ventricular portion having a height ranging between 2 mm to 15 mm, and an annulus support that is positioned between the atrial flange and the ventricular portion. The annulus support includes a ring of anchors extending radially therefrom, with an annular clipping space defined between the atrial flange and the ring of anchors. A plurality of leaflet holders positioned at the atrial end of the atrial flange, and a plurality of valve leaflets secured to the leaflet holders, and positioned inside the atrial flange at a location above the native annulus.

Abstract: A mitral valve replacement device is adapted to be deployed at a mitral valve position in a human heart. The device has an atrial flange defining an atrial end of the device, a ventricular portion defining a ventricular end of the device, the ventricular portion having a height ranging between 2 mm to 15 mm, and an annulus support that is positioned between the atrial flange and the ventricular portion. The annulus support includes a ring of anchors extending radially therefrom, with an annular clipping space defined between the atrial flange and the ring of anchors. A plurality of leaflet holders positioned at the atrial end of the atrial flange, and a plurality of valve leaflets secured to the leaflet holders, and positioned inside the atrial flange at a location above the native annulus.

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: A mitral valve replacement device is adapted to be deployed at a mitral valve position in a human heart. The device has an atrial flange defining an atrial end of the device, a ventricular portion defining a ventricular end of the device, the ventricular portion having a height ranging between 2 mm to 15 mm, and an annulus support that is positioned between the atrial flange and the ventricular portion. The annulus support includes a ring of anchors extending radially therefrom, with an annular clipping space defined between the atrial flange and the ring of anchors. A plurality of leaflet holders positioned at the atrial end of the atrial flange, and a plurality of valve leaflets secured to the leaflet holders, and positioned inside the atrial flange at a location above the native annulus.

Abstract: A mitral valve replacement device is adapted to be deployed at a mitral valve position in a human heart. The device has an atrial flange defining an atrial end of the device, a ventricular portion defining a ventricular end of the device, the ventricular portion having a height ranging between 2 mm to 15 mm, and an annulus support that is positioned between the atrial flange and the ventricular portion. The annulus support includes a ring of anchors extending radially therefrom, with an annular clipping space defined between the atrial flange and the ring of anchors. A plurality of leaflet holders positioned at the atrial end of the atrial flange, and a plurality of valve leaflets secured to the leaflet holders, and positioned inside the atrial flange at a location above the native annulus.